Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
RESEARCH TRIANGLE PARK, N.C., Oct. 27, 2023 -- G1 Therapeutics, Inc. , a commercial-stage oncology company, today announced the presentation of four posters that provide new-real world evidence...